Frequency of molecular response in a patient of chronic myeloid leukemia taking Tyrosine Kinase Inhibitors after 1 year of treatment Pakistan Institute of Medical Sciences experience
DOI:
https://doi.org/10.61581/MJSP.VOL06/01/04Keywords:
Major molecular response (MMR), Chronic myeloid leukemia (CML), Tyrosine kinase inhibitors (TKIs)Abstract
Objective: To determine frequency of major molecular response in a patient of CML taking TKIs after 1 year of treatment PIMS experience
Methodology: A descriptive cross-sectional study. Pakistan Institute of Medical Sciences (PIMS), Islamabad from 07-05-2024 to 07-11-2024. Current study included 121 patients by nonprobability consecutive sampling technique. Patients who didn’t follow up regularly and refused to participate in the study were excluded. After taking consent, age, gender and residential status were documented. Venous blood sample (3cc) was drawn and sent to the laboratory for the quantification of BCR-ABLI through mRNA GeneXpert to determine the major molecular response. Data was analyzed by SPSS 27. Descriptive statistics were applied for the age of patients to calculate mean and S.D. Frequencies were calculated for gender, age groups, residential status, and major molecular response. P value ? 0.05 was labelled significant.
Results: Mean age of the patients was 44.21±11.64 years; and 73(60.3 %) were males and 48(39.7 %) were females. MMR was seen in 43.0% of the patients. MMR was seen in 34.5% of the patients in 18-35 years-group; in28.9 % of 36-50 years-group; and in61.7%of 51-60 years-group(p=0.004).
Conclusion: TKIs have proven to be effective treatment choices for patients of CML, especially in older age groups.
Downloads
References
1. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol. 2016;91(2):252-65.
2. Sumantri AF, Oehadian A, Wijaya I, Vidyaniati P, Rahmaniati R. Therapeutic responses of imatinib and nilotinib among CML patients in HasanSadikin Hospital Bandung. Indonesian J Cancer. 2019;12(3):88-94.
3. Woessner DW, Lim CS, Deininger MW. Development of an effective therapy for CML. Cancer J. 2011;17(6):1-19.
4. Pottier C, Fresnais M, Gilon M, Jérusalem G, Longuespée R, Sounni NE. Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. Cancers. 2020;12(3):731.
5. Chen KK, Du TF, Xiong PS, Fan GH, Yang W. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia with losing major molecular response as a definition for molecular relapse: a systematic review and meta-analysis. Frontiers Oncol. 2019;9:372.
6. Mir AA, Mir AR, Rehmat U, Shakoor I, Amjad F, Khalid M, et al. Treatment Responses in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors (TKI) Therapy. Pak J Med Health Sc. 2021;15(9):2358-60.
7. Hehlmann R. The new ELN recommendations for treating CML. J Clin Med. 2020;9(11):3671.
8. Milojkovic D, Cross NC, Ali S, Byrne J, Campbell G, Dignan FL, et al. Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. British J Haematol. 2021;192(1):62-74.
9. Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, et al. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. Int J Hematol. 2019;109:426-39.
10. Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia. 2011;25(1):7-22.
11. Ayala M, Domínguez J, Chavez A. Nilotinib as second or third-line therapy for myeloid chronic leukemia chronic-phase in Mexican patients. Blood. 2016;128(22):5459.
12. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, et al. International Randomized Study of Interferon and STI571 (IRIS) Investigators. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009;115(3):551-60.
13. Mjali A, Obaid MM, Matti BF, Abbas NT. Treatment Outcomes of Nilotinib as Second Line Therapy for Chronic Myeloid Leukemia Patients in Karbala Province of Iraq. Asian Pacific J Cancer Care. 2022;7(2):267-72.
14. Chansung K, Sirijerachai C, Lekhakula A, Viboonjuntra P, Niparuck P, Pauvilai T, et al. Nilotinib as second-line therapy in patients with chronic myeloid leukemia in chronic phase: Thailand experience. Blood. 2016;128(22):5448.
15. Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. J Am SocHematol. 2015;125(6):915-23.
16. Oyekunle AA, Bolarinwa RA, Oyelese AT, Salawu L, Durosinmi MA. Determinants of Overall and Progression‐Free Survival of Nigerian Patients with Philadelphia‐Positive Chronic Myeloid Leukemia. AdvHematol. 2015;2015(1):908708.
17. Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 2005;19(6):984-9.
18. Haque A, Shah SK, Rahim H, Wahid A. Comparing Imatinib and Nilotinib in the Treatment of Newly Diagnosed Chronic Myeloid Leukemia in Patients of Sandeman Provincial Hospital, Quetta, Pakistan. J PakSoc Intern Med. 2022;3(1):36-40.
19. Singh R, Kapoor J, Ahmed R, Mehta P, Khushoo V, Agrawal P, et al. A retrospective cohort study of upfront nilotinib in chronic myeloid leukemia: a single-center experience. South Asian J Cancer. 2021;10(04):246-50.
20. Al-Awad AS, Al-Sharifi LM. Assessment of Responses and Adverse Effect between Chronic Myeloid Leukemia Patients Receiving Imatinib Versus Nilotinib Attending Merjan Teaching Hospital/Hematological Unit. MedJ Babylon. 2016;13(1):51-8.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Soohn Jamil, Qasim Mehmood Buttar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
